Canada Veterinary Ocular Market Size by Antiviral Products (2024–2032)

A steady evolution defines the Canada Veterinary Ocular Market, as antiviral eye drops and oral therapies reshape product preferences and clinical adoption. In 2024, branded veterinary products recorded the highest value at USD 510.20 thousand, while off-label human ocular drugs remained the lowest at USD 116.10 thousand. This distribution reflected veterinarians’ strong reliance on standardized formulations and branded reliability for ocular disease management in animals. 

In 2025, the Canada Veterinary Ocular market is estimated to maintain branded products as the leading segment at USD 521.07 thousand, with generics following closely at USD 442.09 thousand. The long-term outlook from 2026 to 2032 indicates consistent dominance of branded formulations, projected to reach USD 673.47 thousand by 2032, supported by rising clinical trust and proven therapeutic outcomes. The dominance of branded products is primarily driven by superior efficacy, regulatory assurance, and innovation in targeted ocular therapies. Additionally, extensive distribution networks, ongoing product advancements, and increasing adoption of prescription-based veterinary treatments continue to strengthen their market position across Canada.